| Literature DB >> 35897472 |
Axelle Gelineau1, Anaick Perrochon1, Louise Robin1, Jean-Christophe Daviet1,2, Stéphane Mandigout1.
Abstract
After discharge from the hospital to home, stroke patients may experience weakness and reduced movement in their hemiparetic arms that limits their ability to perform daily activities. Therapists can use exercise games (exergames) to maintain functional abilities and daily use of the arm at home. A systematic review and meta-analysis was conducted to determine the efficiency of upper limb home-based rehabilitation, using exergaming on activity abilities in stroke. Randomized controlled trials were reviewed in the CENTRAL, MEDLINE, CINAHL, EMBASE, and SCOPUS online databases. Clinical measures of observation and self-reporting were studied in post-intervention and follow-up. Nine studies were included in this systematic review (535 participants). The Physiotherapy Evidence Database (PEDro) score was 6.6/10 (SD 1.0, range 5-8), indicating good quality. This systematic review and meta-analysis showed that upper limb home-based exergaming interventions were no more effective in terms of activity than conventional therapy after stroke, according to the observational and subjective assessments in post-intervention and follow-up. Using this same approach, future studies should focus on evaluating home-based exergames through subgroup analysis to be able to propose recommendations.Entities:
Keywords: activity; e-health; exergames; home; stroke; tele-health; upper limb
Mesh:
Year: 2022 PMID: 35897472 PMCID: PMC9329711 DOI: 10.3390/ijerph19159112
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Prisma 2020 Flow Diagram [24].
Characteristics of the included RCT studies (n = 9) (main outcome in bold).
| Author (Year) [ref.] | Study Design | Participants | Interventional Group (IG) | No of Sessions, Frequency and Length | Outcome Measures | Main Findings | Risk of Bias (PEDro) |
|---|---|---|---|---|---|---|---|
| Adie et al. (2016) [ | RCT, multicentric | 235 subacute patients | IG: Wii™ remote control | 15 min warm-up, 45 min/d, 6 wk. |
MAL-14 COPM | Both groups showed an improved arm function (ARAT) | 8 |
| Ballester et al. (2017) [ | RCT | 35 chronic patients | IG: RGS system—Kinect™ motion capture device, a pair of data gloves (DGTech Engineering Solutions) | 1–3 sessions, 5/wk., 3 wk. | BI | Significantly greater in arm function (CAHAI-13) for the IG | 6 |
| McNulty et al. (2015) [ | RCT | 41 chronic patients | IG: WMT—Wii™ remote control (+ self-adhesive wrap if poor grip strength) | 60 min, 10 sessions, 2 wk. |
BBT Grooved pegboard
| Both groups showed an improved arm function (WMFT-tt) and perceived daily use (MALQOM) | 7 |
| Nijenhuis et al. (2016) [ | RCT, pilot | 20 chronic patients | IG: SCRIPT (custom passive dynamic wrist and hand orthosis sensor), SaeboMAS (gravity compensation of the proximal arm) | 30 min, 6/wk., 6 wk. |
BBT MAL | No significant difference between groups | 5 |
| Piron et al. (2009) [ | RCT | 36 chronic patients | IG: VRRS.net®: 3D motion tracking system (Polhemus 3Space Fastrack®), a magnetic receiver attached to a real object, videoconferencing system | 60 min, 5/wk., 4 wk. | ABILHAND | Both groups showed significant improvements in patient’s perceived manual ability (ABILHAND) | 6 |
| Rand et al. (2016) [ | RCT, pilot | 24 chronic patients | IG: Kinect™ (sensor) and EyeToy™ (camera) | 60 min, 6/wk., 5 wk. |
BBT MAL | Both groups showed significant improvements in arm function (ARAT), perceived daily use (MAL) and manual dexterity (BBT) | 6 |
| Standen et al. (2017) [ | RCT | 27 subacute patients | IG: Virtual glove with Wiimotes™ | IG: Max 20 min, 3/d, 8 wk. |
NHPT MAL NEADL | IG showed significantly greater change in perceived daily use (MAL) | 6 |
| Wolf et al. (2015) [ | RCT, multicentric | 99 subacute patients | IG: HMP + HEP | 180 min, 5/wk., 8 wk. | WMFT | Both groups showed significant improvement in arm function (ARAT and WMFT) | 8 |
| Zondervan et al. (2016) [ | RCT, crossover | 18 chronic patients | IG: MusicGlove: an instrumented glove, laptop screen | 180 min, 3/wk., 3 wk. |
NHPT ARAT MAL | Both groups showed significant improvement in dexterity (BBT) | 7 |
Note. RCT = randomized controlled trial; GRASP = Graded Repetitive Arm Supplementary Program; RGS = Rehabilitation Gaming System; AEMF = Automated Evaluation of Motor Function; WMT = Wii-based Movement Therapy; mCIMT = Modified-constraint therapy; FMA-UE = Fugl-Meyer Assessment for upper extremity; HMP = Hand Mentor Pro; HEP = Home exercise program; ARAT = Action Research Arm Test; WFMT = Wolf Motor Function Test; n/a = no answer; COPM = Canadian Occupational Performance Measure; CAHAI = Chedoke Arm and Hand Activity Inventory; MALQOM = Motor Activity Log Quality of Movement scale; NEADL = Nottingham Extended Activities of Daily Living; BBT = Box and Block Test; NHPT = Nine Hole Peg Test; IG = Interventional Group; CG = Control Group; ST = Short-Term; LT = Long-Term.
Figure 2Forest plots between Intervention and Control Groups in post intervention. (a) SMD for the observed outcome; (b) MD for the self-reported outcomes MALAOU; (c) MD for the self-reported outcomes MALQOM. A pooled result favoring Intervention Group indicates negative values, and favoring Control group indicates positive differences between Intervention and Control Groups. Note: SMD = Standardized Mean Differences; MD = Mean Difference; MALAOU = Motor Activity Log Amount of Use; MALQOM = Motor Activity Log Quality Of Movement [31,32,33,34,35,36,38,39].
Figure 3Forest plot between Intervention and Control Groups in follow-up. (a) SMD for the observed outcome; (b) MD for the self-reported outcomes MALAOU; (c) MD for the self-reported outcomes MALQOM. A pooled result favoring Intervention Group indicates negative values, and favoring Control group indicates positive differences between Intervention and Control Groups. Note: SMD = Standardized Mean Differences; MD = Mean Difference; MALAOU = Motor Activity Log Amount of Use; MALQOM = Motor Activity Log Quality Of Movement [31,34,35,36,38].
Quality assessment of selected randomized controlled trials using the Physiotherapy Evidence Database (PEDro) scale: a higher score implies improved quality.
| Authors (Year) | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | C9 | C10 | C11 | PEDro Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adie et al. (2016) [ | YES | YES | YES | YES | NO | NO | YES | YES | YES | YES | YES | 8 |
| Ballester et al. (2017) [ | YES | YES | YES | YES | NO | NO | NO | YES | NO | YES | YES | 6 |
| McNulty et al. (2015) [ | YES | YES | YES | YES | NO | YES | YES | YES | NO | YES | NO | 7 |
| Nijenhuis et al. (2016) [ | YES | YES | YES | YES | NO | NO | NO | YES | NO | YES | NO | 5 |
| Piron et al. (2009) [ | YES | YES | YES | YES | NO | NO | YES | NO | NO | YES | YES | 6 |
| Rand et al. (2017) [ | YES | YES | NO | YES | NO | NO | YES | YES | NO | YES | YES | 6 |
| Standen et al. (2017) [ | YES | YES | YES | NO | NO | NO | YES | YES | NO | YES | YES | 6 |
| Wolf et al. (2015) [ | YES | YES | YES | YES | NO | NO | YES | YES | YES | YES | YES | 8 |
| Zondervan et al. (2016) [ | YES | YES | YES | YES | NO | NO | YES | YES | NO | YES | YES | 7 |
Note: C1 = Eligibility criteria; C2 = Random allocation; C3 = Concealed allocation; C4 = Baseline comparability; C5 = Blinded subjects; C6 = Blinded therapists; C7 = Blinded assessors; C8 = Adequate follow-up (Drop-out rate); C9 = Intention-to-treat analysis; C10 = Between-group comparisons; C11 = Point estimates and variability.
PRISMA 2020 Checklist [24].
| Section and Topic | Item # | Checklist Item | Location Where Item Is Reported |
|---|---|---|---|
|
| |||
| Title | 1 | Identify the report as a systematic review. | 1 |
|
| |||
| Abstract | 2 | See the PRISMA 2020 for Abstracts checklist. | 12 |
|
| |||
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | 29 |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | 111 |
|
| |||
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | 125 |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | 120 |
| Search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used. | 116 |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. | 138 |
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | 144 |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g., for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | 164 |
| 10b | List and define all other variables for which data were sought (e.g., participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | 144 | |
| Study risk of bias assessment | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. | 154 |
| Effect measures | 12 | Specify for each outcome the effect measure(s) (e.g., risk ratio, mean difference) used in the synthesis or presentation of results. | 179 |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis (e.g., tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). | 180 |
| 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. | 186 | |
| 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | 199 | |
| 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | 179 | |
| 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g., subgroup analysis, meta-regression). | 195 | |
| 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | 154 | |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). | 154 |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | 200 |
|
| |||
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | 202 |
| 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. | 219 | |
| Study characteristics | 17 | Cite each included study and present its characteristics. | 287 |
| Risk of bias in studies | 18 | Present assessments of risk of bias for each included study. | 405 |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g., confidence/credible interval), ideally using structured tables or plots. | 347,371 |
| Results of syntheses | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. | 347,371 |
| 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g., confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | 347,371 | |
| 20c | Present results of all investigations of possible causes of heterogeneity among study results. | 347,371 | |
| 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | 347,371 | |
| Reporting biases | 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | 347,371 |
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | 347,371 |
|
| |||
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence. | 411 |
| 23b | Discuss any limitations of the evidence included in the review. | 505 | |
| 23c | Discuss any limitations of the review processes used. | 505 | |
| 23d | Discuss implications of the results for practice, policy, and future research. | 525 | |
|
| |||
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | |
| 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | ||
| 24c | Describe and explain any amendments to information provided at registration or in the protocol. | ||
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. | |
| Competing interests | 26 | Declare any competing interests of review authors. | 576 |
| Availability of data, code and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | |